RU2016114498A - Способы и композиции для лечения раковых заболеваний - Google Patents
Способы и композиции для лечения раковых заболеваний Download PDFInfo
- Publication number
- RU2016114498A RU2016114498A RU2016114498A RU2016114498A RU2016114498A RU 2016114498 A RU2016114498 A RU 2016114498A RU 2016114498 A RU2016114498 A RU 2016114498A RU 2016114498 A RU2016114498 A RU 2016114498A RU 2016114498 A RU2016114498 A RU 2016114498A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- paragraphs
- cells
- subject
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 21
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 210000005265 lung cell Anatomy 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 101150025421 ETS gene Proteins 0.000 claims 1
- 102100039563 ETS translocation variant 1 Human genes 0.000 claims 1
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 1
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 claims 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 1
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 claims 1
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 1
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 claims 1
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims 1
- 101000898093 Homo sapiens Protein C-ets-2 Proteins 0.000 claims 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 1
- 102100035251 Protein C-ets-1 Human genes 0.000 claims 1
- 102100021890 Protein C-ets-2 Human genes 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- -1 β-hydroxypropyl cyclodextrin Chemical compound 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895308P | 2013-10-24 | 2013-10-24 | |
| US61/895,308 | 2013-10-24 | ||
| PCT/US2014/061418 WO2015061229A1 (en) | 2013-10-24 | 2014-10-20 | Methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016114498A true RU2016114498A (ru) | 2017-11-29 |
| RU2016114498A3 RU2016114498A3 (OSRAM) | 2018-08-13 |
Family
ID=52993423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016114498A RU2016114498A (ru) | 2013-10-24 | 2014-10-20 | Способы и композиции для лечения раковых заболеваний |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9511050B2 (OSRAM) |
| EP (1) | EP3060207A4 (OSRAM) |
| JP (1) | JP6389884B2 (OSRAM) |
| KR (1) | KR20160065986A (OSRAM) |
| CN (1) | CN105848654B (OSRAM) |
| AU (1) | AU2014340398A1 (OSRAM) |
| CA (1) | CA2927148A1 (OSRAM) |
| IL (1) | IL245281A0 (OSRAM) |
| MX (1) | MX2016004678A (OSRAM) |
| RU (1) | RU2016114498A (OSRAM) |
| WO (1) | WO2015061229A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| WO2013155341A1 (en) | 2012-04-12 | 2013-10-17 | Georgetown University | Methods and compositions for treating ewings sarcoma family of tumors |
| CA2927148A1 (en) * | 2013-10-24 | 2015-04-30 | Georgetown University | Methods and compositions for treating cancer |
| MX388564B (es) | 2014-10-09 | 2025-03-20 | Oncternal Therapeutics Inc | Compuestos de indolinona y usos de los mismos. |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． | Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| JP6864379B2 (ja) | 2016-03-31 | 2021-04-28 | オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | インドール類似体及びその使用 |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| US10761081B2 (en) * | 2016-06-12 | 2020-09-01 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| US10613088B2 (en) * | 2016-06-12 | 2020-04-07 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| KR102282794B1 (ko) | 2016-07-29 | 2021-07-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌리논 화합물의 용도 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CA3054836A1 (en) * | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Detecting prostate cancer |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110845389A (zh) * | 2019-10-17 | 2020-02-28 | 袁健 | 一种新型i型拓扑异构酶抑制剂 |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| WO2000033834A1 (en) | 1998-12-04 | 2000-06-15 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| JP4584987B2 (ja) | 2004-04-30 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | Ｃ５修飾ピリミジンを含むオリゴヌクレオチド |
| US20090217390A1 (en) | 2005-04-29 | 2009-08-27 | Fernando Lecanda Cordero | Non-human animal sarcoma model |
| CA2711003C (en) * | 2006-12-29 | 2017-02-21 | Georgetown University | Targeting of ews-fli1 as anti-tumor therapy |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| JP5400032B2 (ja) | 2007-04-20 | 2014-01-29 | ザ リサーチ ファウンデーション オブ ザ ステイト ユニヴァーシティ オブ ニューヨーク | ベンズイミダゾール及びその医薬組成物 |
| WO2013151981A1 (en) * | 2012-04-02 | 2013-10-10 | Gradalis, Inc. | Ewing's sarcoma bifunctional shrna design |
| WO2013155341A1 (en) | 2012-04-12 | 2013-10-17 | Georgetown University | Methods and compositions for treating ewings sarcoma family of tumors |
| CA2927148A1 (en) * | 2013-10-24 | 2015-04-30 | Georgetown University | Methods and compositions for treating cancer |
-
2014
- 2014-10-20 CA CA2927148A patent/CA2927148A1/en not_active Abandoned
- 2014-10-20 AU AU2014340398A patent/AU2014340398A1/en not_active Abandoned
- 2014-10-20 EP EP14855801.8A patent/EP3060207A4/en not_active Withdrawn
- 2014-10-20 US US15/030,713 patent/US9511050B2/en active Active
- 2014-10-20 MX MX2016004678A patent/MX2016004678A/es unknown
- 2014-10-20 JP JP2016526034A patent/JP6389884B2/ja active Active
- 2014-10-20 CN CN201480071102.0A patent/CN105848654B/zh active Active
- 2014-10-20 KR KR1020167013692A patent/KR20160065986A/ko not_active Withdrawn
- 2014-10-20 WO PCT/US2014/061418 patent/WO2015061229A1/en not_active Ceased
- 2014-10-20 RU RU2016114498A patent/RU2016114498A/ru not_active Application Discontinuation
-
2016
- 2016-04-21 IL IL245281A patent/IL245281A0/en unknown
- 2016-11-30 US US15/365,794 patent/US20170157089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105848654A (zh) | 2016-08-10 |
| CN105848654B (zh) | 2018-10-02 |
| JP6389884B2 (ja) | 2018-09-12 |
| US20170157089A1 (en) | 2017-06-08 |
| KR20160065986A (ko) | 2016-06-09 |
| EP3060207A1 (en) | 2016-08-31 |
| IL245281A0 (en) | 2016-06-30 |
| WO2015061229A1 (en) | 2015-04-30 |
| CA2927148A1 (en) | 2015-04-30 |
| US20160263086A1 (en) | 2016-09-15 |
| RU2016114498A3 (OSRAM) | 2018-08-13 |
| MX2016004678A (es) | 2017-03-10 |
| AU2014340398A1 (en) | 2016-06-09 |
| US9511050B2 (en) | 2016-12-06 |
| JP2016534084A (ja) | 2016-11-04 |
| EP3060207A4 (en) | 2017-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016114498A (ru) | Способы и композиции для лечения раковых заболеваний | |
| Jhaveri et al. | Stimuli-sensitive nanopreparations for combination cancer therapy | |
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| JP2015516989A5 (OSRAM) | ||
| Eskiizmir et al. | Nanomaterials: promising structures for the management of oral cancer | |
| WO2016077840A3 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| TR201818927T4 (tr) | Kataterlerde İyileştirme | |
| RU2018131636A (ru) | Новые конъюгаты аманитина | |
| JP2018513104A5 (OSRAM) | ||
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| RU2015143490A (ru) | Способы лечения рака мочевого пузыря | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| RU2016132635A (ru) | Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| PH12013500108A1 (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| ES2928499T3 (es) | Inhibición de la proliferación de células madre cancerosas | |
| RU2018123666A (ru) | Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина | |
| DOP2011000282A (es) | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos | |
| EA201690085A1 (ru) | Полимерные наночастицы доцетаксела для лечения рака | |
| WO2016059241A3 (en) | Lung cancer diagnostics and therapeutics with mir-660 | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2016526021A5 (OSRAM) | ||
| RU2017112088A (ru) | Лечение неопластических заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190507 |